| CURIS INC. NEW DL -,01 |
| USA |
| US2312694084 / A42DTL |
| CUS1 (Frankfurt) / CRIS (NASDAQ) |
| FRA:CUS1, ETR:CUS1, CUS1:GR, NASDAQ:CRIS |
| - |
| - |
|
Curis Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for cancer treatment. The company’s current portfolio centers on targeted drug candidates designed to address specific cancer-driving pathways a..
>Volltext.. |
| 3.93 Mio. EUR |
| -0.06 Mio. EUR |
| 3.84 Mio. EUR |
| -31.92 Mio. EUR |
| -18.82 Mio. EUR |
| -12.71 EUR |
| 0.93 Mio. EUR |
| 5 Mio. EUR |
| -27.22 Mio. EUR |
| 0.41 |
| -60.98% |
| 43.94% |
| - |
| - |
| - |
| - |
| 04.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|